Kodiak's Two wAMD Candidates Hit Phase 3 Goals, Matching Eylea With Longer Dosing Interval
- Kodiak Sciences' Phase 3 DAYBREAK trial met primary endpoints for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in wet age-related macular degeneration, with vision gains comparable to Regeneron's Eylea (aflibercept).
- The majority of Zenkuda patients achieved a six-month dosing interval, versus Eylea's standard eight-week schedule.
- Kodiak plans to file a Biologics License Application with the FDA in Q4 2026.
💡 Points
Matching Eylea's efficacy is table stakes; the six-month interval is the real lever, potentially beating Eylea HD's and Vabysmo's quarterly dosing on the metric that drives adherence — treatment burden. That strengthens Kodiak's BLA package and partnership leverage more than raw efficacy parity would. Risk: without a durability edge, six-month dosing could compress once real-world data arrives.
Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor ↗